U-50488

U-50488
(IUPAC) ime
	2-(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-ylcyclohexyl]acetamide
Klinički podaci
Identifikatori
CAS broj	67198-13-4
ATC kod	?
PubChem	3036289
ChEMBL	CHEMBL441765
Hemijski podaci
Formula	C19H26Cl2N2O
Mol. masa	369.329 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C19H26Cl2N2O/c1-22(19(24)13-14-8-9-15(20)16(21)12-14)17-6-2-3-7-18(17)23-10-4-5-11-23/h8-9,12,17-18H,2-7,10-11,13H2,1H3/t17-,18-/m1/s1 ; Key: VQLPLYSROCPWFF-QZTJIDSGSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

U-50488 je lek koji deluje kao visoko selektivni agonist κ-opioidnog receptora, bez μ-opioidnih antagonističkog dejstva.^[4] On ima analgetske, diuretske i antitusivne efekte,^[5] i poništava memorijski uticaj antiholinergičkih lekova.^[6] U-50488 je bio jedan od prvih selektivnih kapa agonista i istraživanja osobina njegovih derivata su dovela do razvoja velike familije srodnih jedinjenja.^[7]^[8]

Literatura

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Von Voigtlander, PF; Lewis, RA (1982). „U-50,488, a selective kappa opioid agonist: comparison to other reputed kappa agonists”. Progress in neuro-psychopharmacology & biological psychiatry 6 (4-6): 467–70. PMID 6298890.
↑ Kamei, J (1996). „Role of opioidergic and serotonergic mechanisms in cough and antitussives”. Pulmonary pharmacology 9 (5-6): 349–56. DOI:10.1006/pulp.1996.0046. PMID 9232674.
↑ Hiramatsu, M; Kameyama, T (1998). „Roles of kappa-opioid receptor agonists in learning and memory impairment in animal models”. Methods and findings in experimental and clinical pharmacology 20 (7): 595–9. PMID 9819804.
↑ Szmuszkovicz, J (1999). „U-50,488 and the kappa receptor: a personalized account covering the period 1973 to 1990”. Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques 52: 167–95. PMID 10396128.
↑ Szmuszkovicz, J (1999). „U-50,488 and the kappa receptor. Part II: 1991-1998”. Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques 53: 1–51. PMID 10616295.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[4] Von Voigtlander, PF; Lewis, RA (1982). „U-50,488, a selective kappa opioid agonist: comparison to other reputed kappa agonists”. Progress in neuro-psychopharmacology & biological psychiatry 6 (4-6): 467–70. PMID 6298890.

[5] Kamei, J (1996). „Role of opioidergic and serotonergic mechanisms in cough and antitussives”. Pulmonary pharmacology 9 (5-6): 349–56. DOI:10.1006/pulp.1996.0046. PMID 9232674.

[6] Hiramatsu, M; Kameyama, T (1998). „Roles of kappa-opioid receptor agonists in learning and memory impairment in animal models”. Methods and findings in experimental and clinical pharmacology 20 (7): 595–9. PMID 9819804.

[7] Szmuszkovicz, J (1999). „U-50,488 and the kappa receptor: a personalized account covering the period 1973 to 1990”. Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques 52: 167–95. PMID 10396128.

[8] Szmuszkovicz, J (1999). „U-50,488 and the kappa receptor. Part II: 1991-1998”. Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques 53: 1–51. PMID 10616295.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]